Literature DB >> 27301196

Folate-Modified Chitosan Nanoparticles Coated Interferon-Inducible Protein-10 Gene Enhance Cytotoxic T Lymphocytes' Responses to Hepatocellular Carcinoma.

Siliang Duan, Mongkhoune Song, Jian He, Nuo Zhou, Sufang Zhou, Jing Zhao, Yuan Fang, Peng Yi, Xianing Huang, Guorong Luo, Chunhui Lai, Xia Yu, Zhiyong Zhang, Yuan Xie, Yongxiang Zhao, Xiaoling Lu.   

Abstract

Adoptive therapy using tumor antigen-specific cytotoxic T lymphocytes (CTLs) is a promising approach for treatment of human cancers. Due to immune suppression in cancer patients, it is difficult for tumor antigen-specific CTLs to arrive at tumor tissues. Interferon-inducible protein-10 (IP-10) is a powerful chemokine that effectively attracts CTLs to tumor tissues and improves their anti-tumor activity. Increase over expression of IP-10 in tumor tissues can efficiently promote efficacy of adoptive therapy. Folate-modified chitosan nanoparticles coating the human IP-10 gene (FA-CS-hIP-10) were therefore developed in this study. The FA-CS-hIP-10 nanoparticles were specifically bound to folate receptors on hepatoma cells and promoted the expression of IP-10, to improve the activity of pMAGE-A1(278-286) specific CTLs. Combination of the FA-CS-hIP-10 and pMAGE-A1(278-286) specific CD8+ CTLs efficiently increased secretion of IFN-γ, inhibited tumor growth and extended survival of nude mice with subcutaneously transplanted human hepatocellular carcinoma. Our results demonstrated that the mechanism behind this novel therapeutic approach involved inhibition of angiogenesis and proliferation, and also promoted apoptosis of tumor cells. Our study provides a potentially novel approach for treatment of human hepatocellular carcinoma by improving the activity of tumor antigen-specific CTLs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27301196     DOI: 10.1166/jbn.2016.2216

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  6 in total

Review 1.  Nanotechnology synergized immunoengineering for cancer.

Authors:  Deepak S Chauhan; Anupam Dhasmana; Partha Laskar; Rajendra Prasad; Nishant K Jain; Rohit Srivastava; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu
Journal:  Eur J Pharm Biopharm       Date:  2021-03-24       Impact factor: 5.589

2.  Echogenic, Ultrasound-Sensitive Chitosan Nanodroplets for Spatiotemporally Controlled DKK-2 Gene Delivery to Prostate Cancer Cells.

Authors:  Xinxin Liu; Dandan Shi; Lu Guo; Xiaoying Zhou; Mengmeng Shang; Xiao Sun; Dong Meng; Yading Zhao; Jie Li
Journal:  Int J Nanomedicine       Date:  2021-01-15

Review 3.  Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies.

Authors:  Zhengyang Yang; Wei Deng; Xiao Zhang; Yongbo An; Yishan Liu; Hongwei Yao; Zhongtao Zhang
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

4.  Delivery of interleukin-22 binding protein (IL-22BP) gene by cationic micelle for colon cancer gene therapy.

Authors:  Ke Men; Rong Huang; Xueyan Zhang; Rui Zhang; Yuanfa Zhang; Yao Peng; Rongsheng Tong; Li Yang; Yuquan Wei; Xingmei Duan
Journal:  RSC Adv       Date:  2018-05-04       Impact factor: 4.036

5.  Facile Gene Delivery Derived from Branched Low Molecular Weight Polyethylenimine by High Efficient Chemistry.

Authors:  Lei Zou; So Yoon Lee; Qi Wu; Haoyun Zhang; Anthony Bastian; Cara Orji; Gregory Payne; Adriana Galvez; Tima Thomas; Zijian Zhang; Huanyu Dou
Journal:  J Biomed Nanotechnol       Date:  2018-10-01       Impact factor: 4.099

6.  Chitosan Nanovaccines as Efficient Carrier Adjuvant System for IL-12 with Enhanced Protection Against HBV.

Authors:  Huajun Zhao; Haigang Wang; Yifei Hu; Dongqing Xu; Chunlai Yin; Qiuju Han; Jian Zhang
Journal:  Int J Nanomedicine       Date:  2021-07-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.